19 patents
Utility
Ion channel modulators
9 Jan 24
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella, Kiran Reddy, Marion Wittmann
Filed: 30 May 19
Utility
KCNT1 inhibitors and methods of use
3 Oct 23
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1).
Gabriel Martinez Botella, Andrew Mark Griffin
Filed: 2 Nov 21
Utility
Compounds and their methods of use
3 Oct 23
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
Filed: 28 May 20
Utility
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
26 Sep 23
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron, Carlos Loya
Filed: 25 Nov 20
Utility
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator
22 Aug 23
The present invention is directed to 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trofluoroethoxy)pyridine-3-yl)-[1,2,4]triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, or a composition thereof, which is useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
Filed: 23 Mar 22
Utility
Compounds and their methods of use
22 Aug 23
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran Reddy, Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
Filed: 4 Apr 18
Utility
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator
22 Aug 23
The present invention is directed to 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trofluoroethoxy)pyridine-3-yl)-[1,2,4]triazolo[4,3-a]pyridine, or a pharmaceutically acceptable salt thereof, or a composition thereof, which is useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
Filed: 26 Mar 21
Utility
Hemi-citrate salts of GABA-A positive allosteric modulator and crystalline form thereof
11 Jul 23
Disclosed herein are hemi-citrate salts of Compound 1, crystalline forms thereof, methods of their preparation, pharmaceutical compositions thereof, and methods of their use.
Doris Neville, Ahmad Hashash, Karl Hansen, Johann Chan
Filed: 25 May 22
Utility
Formulations of T-type calcium channel modulators and methods of use thereof
16 May 23
Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)).
Preetam Ghogale
Filed: 28 Jul 21
Utility
Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity
18 Apr 23
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
Filed: 28 Nov 17
Utility
Substituted pyridines as ion channel modulators
22 Nov 22
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella, Kiran Reddy
Filed: 29 May 20
Utility
Compounds and their methods of use
8 Nov 22
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
Filed: 13 Feb 18
Utility
Formulations of T-type calcium channel modulators and methods of use thereof
30 Aug 22
Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)).
Kiran Reddy, Margaret S. Lee, Gabriel Maurice Belfort, Sapna Makhija Garad, Mahesh Padval, Randall Wagner
Filed: 28 Jul 21
Utility
Compounds and their methods of use
22 Mar 22
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
Filed: 15 Aug 18
Utility
Ion channel modulators
22 Mar 22
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella, Kiran Reddy
Filed: 29 May 20
Utility
Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
1 Mar 22
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
Filed: 28 Nov 17
Utility
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator
25 May 21
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
Filed: 24 Nov 20
Utility
Salts and crystal forms of GABA
23 Feb 21
The invention relates to salts of Compound 1, crystalline forms thereof, methods of their preparation, pharmaceutical compositions thereof and methods of their use.
Nelson B. Olivier, Kiran Reddy, Gabriel Martinez Botella, Magnus Ronn, Paul A. Laskar
Filed: 27 Nov 19
Utility
Salts and crystal forms of GABA
17 Feb 20
The invention relates to salts of Compound 1, crystalline forms thereof, methods of their preparation, pharmaceutical compositions thereof and methods of their use.
Nelson B. Olivier, Kiran Reddy, Gabriel Martinez Botella, Magnus Ronn, Paul A. Laskar
Filed: 18 Jul 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first